Semaglutide clinical trials
Pro Research Analysisby 
Searched over 200M research papers
Semaglutide Clinical Trials: Efficacy, Safety, and Key Outcomes
Efficacy of Semaglutide in Type 2 Diabetes Management
Multiple large-scale clinical trials have shown that semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, provides significant improvements in glycemic control and body weight reduction for people with type 2 diabetes. Across the SUSTAIN 1–7 trials, semaglutide consistently led to greater reductions in HbA1c and body weight compared to placebo and other active comparators, including dulaglutide, with a similar safety profile Aroda2019Sorli2017Frias2021+3 MORE. In SUSTAIN 1, semaglutide monotherapy resulted in significant HbA1c and weight reductions in treatment-naive patients . The SUSTAIN 7 trial demonstrated that semaglutide was superior to dulaglutide in both glycemic control and weight loss .
Weight Loss in Overweight and Obese Adults
Semaglutide has also been studied for weight management in adults with overweight or obesity, both with and without diabetes. In the OASIS 1 trial, oral semaglutide 50 mg once daily led to a substantial and clinically meaningful decrease in body weight compared to placebo in adults without type 2 diabetes . Similarly, the STEP 2 trial found that once-weekly semaglutide 2.4 mg produced greater weight loss than the 1.0 mg dose or placebo in adults with type 2 diabetes and overweight or obesity .
Cardiovascular and Renal Outcomes
The SUSTAIN 6 trial showed that semaglutide significantly reduced the risk of major cardiovascular events in patients with type 2 diabetes at high cardiovascular risk . Additionally, a recent trial in patients with chronic kidney disease (CKD) but without diabetes found that semaglutide reduced albuminuria, suggesting potential kidney-protective effects in this population .
Oral Semaglutide: Pharmacokinetics and Efficacy
Oral semaglutide, the first oral GLP-1 receptor agonist, has demonstrated similar efficacy to the injectable form in reducing HbA1c and body weight in patients with type 2 diabetes Overgaard2021Aroda2019. Its absorption is influenced by fasting time and water volume, but steady-state exposure is consistent between healthy individuals and those with diabetes .
Combination Therapy and Dose Escalation
Adding semaglutide to other glucose-lowering therapies, such as SGLT-2 inhibitors, further improves glycemic control and weight loss in patients with inadequately controlled type 2 diabetes . Higher doses of semaglutide (2.0 mg) have been shown to provide additional reductions in HbA1c and body weight compared to the standard 1.0 mg dose, offering an option for patients needing further glycemic control .
Safety and Tolerability
Across trials, the most common adverse events with semaglutide are gastrointestinal, such as nausea and diarrhea, which are usually mild to moderate and transient Aroda2019Knop2023Sorli2017+5 MORE. Serious adverse events are rare and occur at similar rates to placebo or other comparators.
Conclusion
Semaglutide, in both injectable and oral forms, is highly effective for improving glycemic control and promoting weight loss in people with type 2 diabetes and those with overweight or obesity. It also offers cardiovascular and potential renal benefits, with a safety profile consistent with other GLP-1 receptor agonists. These findings support semaglutide as a valuable option in the management of type 2 diabetes and obesity.
Sources and full results
Most relevant research papers on this topic